Last Updated: November 16, 2026

Details for Patent: 11,052,064

« Back to Dashboard


Which drugs does patent 11,052,064 protect, and when does it expire?

Patent 11,052,064 protects YCANTH and is included in one NDA.

This patent has twenty-eight patent family members in eleven countries.

Summary for Patent: 11,052,064
Title:Compositions, methods and systems for the treatment of cutaneous disorders
Abstract:Devices, systems, methods, and kits for treating cutaneous diseases, such as warts, with a cantharidin formulation are generally described. The cantharidin formulations, described herein, may have many advantages over traditional cantharidin formulations, including removal of highly volatile and corrosive solvents, improved safety, and improved compatibility with common plastics for ease of delivery. The devices, systems, methods, and kits can be used for the precise application of the cantharidin formulation for the treatment of cutaneous diseases and other topical indications. Treatment of cutaneous diseases with cantharidin, using the devices, systems, methods, and/or kits may have many advantages over traditional therapies, including high single application efficacy, lack of scaring, and a mild pain profile.
Inventor(s):Matthew Gene Davidson
Assignee: Verrica Pharmaceuticals Inc
Application Number:US14/913,335
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,052,064
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device;

Drugs Protected by US Patent 11,052,064

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Verrica Pharms YCANTH cantharidin SOLUTION;TOPICAL 212905-001 Jul 21, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TOPICAL DELIVERY OF A CANTHARIDIN FORMULATION TO ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR TREATING MOLLUSCUM CONTAGIOSUM ⤷  Start Trial
Verrica Pharms YCANTH cantharidin SOLUTION;TOPICAL 212905-001 Jul 21, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,052,064

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014308690 ⤷  Start Trial
Australia 2019250220 ⤷  Start Trial
Australia 2021202518 ⤷  Start Trial
Australia 2023200914 ⤷  Start Trial
Brazil 112016003381 ⤷  Start Trial
Canada 2921957 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.